| __timestamp | Amphastar Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 660772000 |
| Thursday, January 1, 2015 | 46974000 | 736435000 |
| Friday, January 1, 2016 | 47298000 | 775266000 |
| Sunday, January 1, 2017 | 50918000 | 860348000 |
| Monday, January 1, 2018 | 58044000 | 814775000 |
| Tuesday, January 1, 2019 | 63109000 | 942821000 |
| Wednesday, January 1, 2020 | 65157000 | 985616000 |
| Friday, January 1, 2021 | 68920000 | 1061508000 |
| Saturday, January 1, 2022 | 66592000 | 1190423000 |
| Sunday, January 1, 2023 | 80393000 | 1254234000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Grifols consistently outspent Amphastar, with SG&A expenses peaking at approximately 1.25 billion in 2023, a 90% increase from 2014. In contrast, Amphastar's expenses grew by about 99%, reaching 80 million in 2023. This disparity highlights Grifols' aggressive investment in administrative and sales functions, potentially driving its market dominance. Meanwhile, Amphastar's leaner approach may reflect a focus on operational efficiency. As the industry evolves, these financial strategies will play a pivotal role in shaping the competitive dynamics between these two pharmaceutical giants.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE